Omitting CTV Reduces Toxicity in SCLC Radiotherapy, Analysis Finds
Omitting the clinical target volume during radiotherapy for limited-stage small cell lung cancer maintains similar tumor response and survival outcomes while reducing treatment-related toxicity, according to a retrospective analysis published in Radiotherapy and Oncology.
Key Clinical Takeaways:
- Progression-free survival and overall survival remained statistically similar between patients receiving conventional clinical target volume planning and those where the volume was omitted.
- Omitting the clinical target volume lowered the incidence of both radiation pneumonitis and esophagitis across trial cohorts.
- An exploratory subset of patients receiving immune checkpoint inhibitor therapy showed a promising signal for longer survival outcomes when the clinical target volume was omitted.
Retrospective Cohort Analysis at Tertiary Hospitals
Radiation therapy for limited-stage small cell lung cancer conventionally incorporates a clinical target volume surrounding the gross tumor to address potential microscopic disease spread. Investigators sought to determine whether dropping that additional volume could maintain disease control while sparing surrounding normal tissue from unnecessary radiation exposure. Researchers at three tertiary hospitals affiliated with Shandong First Medical University in China conducted a multicenter, retrospective real-world cohort study evaluating the approach.
The initial study pool comprised 946 patients, featuring 403 individuals in the omit-clinical target volume group and 543 in the conventional treatment group. To control for confounding variables, investigators performed propensity score matching. This statistical adjustment balanced age, performance status, smoking history, TNM stage, and gross tumor volume, resulting in 265 matched patients per group for the primary analysis. Median follow-up across the cohort spanned 33.2 months.
Omit-Clinical Target Volume Shows Similar Survival Outcomes
Primary endpoints for the analysis focused on progression-free survival and overall survival. Median progression-free survival reached 11.8 months in the omit-clinical target volume group compared with 11.6 months in the conventional group, yielding a hazard ratio of 0.93 that was not statistically significant. Median overall survival reached 35.8 months in the omit-clinical target volume group and 30.7 months in the conventional group, with a hazard ratio of 0.85.
Overall response rates showed minimal divergence between the two approaches. Patients in the omit-clinical target volume group achieved a 72.8% overall response rate, while those receiving conventional planning reached 69.4%.
Reduction in Radiation Pneumonitis and Esophagitis
Toxicity assessments revealed differences in treatment-related adverse events between the cohorts. Omitting the clinical target volume was associated with lower rates of both radiation pneumonitis and esophagitis. Grade 1-2 pneumonitis occurred in 20.0% of the omit-clinical target volume group versus 27.2% of the conventional group. More severe grade 3 or higher pneumonitis dropped from 8.3% down to 3.4%.
Esophagitis rates followed a similar trajectory. Grade 1-2 esophagitis affected 32.1% of patients in the omit-clinical target volume arm compared with 39.2% in the conventional arm. Grade 3 or higher esophagitis occurred in 5.7% of the omit-clinical target volume group versus 9.1% of the conventional group.
Exploratory Subgroup Findings in Immunotherapy Patients
Investigators conducted an exploratory subgroup analysis of 77 patients who received immune checkpoint inhibitor therapy alongside radiation, dividing them into 37 patients in the omit-clinical target volume group and 40 in the conventional group. Within this specific subset, median progression-free survival and overall survival favored the omission group, showing outcomes that were not reached compared with 15.2 months for progression-free survival and 26.9 months for overall survival in the conventional arm. Study authors noted that the small subgroup size limits interpretation and requires prospective validation.
The study was funded by three Shandong- and Beijing-based foundations that had no role in study design or conduct. Xiaolong Wang and Xiangjiao Meng reported no competing interests.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.